AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18705533 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy (10-160 mg)
Number of subjects: 16416
Study 18705533 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus HCTZ (10-160 mg + 6.25-25 mg)
Number of subjects: 16416
Study 18705533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16416
Study 18705533 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan monotherapy (open-label)
Number of subjects: 16416
Study 18705533 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan plus HCTZ (open-label)
Number of subjects: 16416
Study 18705533 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 16416
Study 15983428 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 73
Study 15983428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculations reported in RCTs
Number of subjects: 127
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with positive treatment effect
Number of subjects: 127
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies appropriately powered to detect a 50% effect change
Number of subjects: 127
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with power to detect a 20% difference
Number of subjects: 127
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Underpowered studies needing increased sample size
Number of subjects: 127
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall reporting of sample size calculations
Number of subjects: 127
Study 12947329 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with appropriate sample sizes
Number of subjects: 127
Study 10593790 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas inhalation with aerosolized methacholine
Number of subjects: 12
Study 10593790 — intervention group
Group type: COMPARATOR
Intervention: Normoxic gas inhalation with aerosolized methacholine
Number of subjects: 12
Study 8722544 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 g)
Number of subjects: 38
Study 8722544 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (0.6 g)
Number of subjects: 38
Study 8722544 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin and Clindamycin
Number of subjects: 38
Study 1358932 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms
Number of subjects: 20
Study 1358932 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 20
Study 1358932 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 200 micrograms
Number of subjects: 20
Study 1358932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1358932 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 25 micrograms vs Salbutamol
Number of subjects: 20
Study 1358932 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms vs Salbutamol
Number of subjects: 20
Study 1358932 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms vs Salmeterol 25 micrograms
Number of subjects: 20
Study 6097818 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyno‐Travogen® vaginal tablets (300 mg isoconazole nitrate each)
Number of subjects: 140
Study 6097818 — intervention group
Group type: COMPARATOR
Intervention: Nizoral® tablets (200 mg ketoconazole each)
Number of subjects: 140
Study 30251736 — intervention group
Group type: EXPERIMENTAL
Intervention: Er: YAG laser etched enamel (1.5W, 15Hz)
Number of subjects: 50
Study 30251736 — intervention group
Group type: COMPARATOR
Intervention: Acid etched enamel (37% phosphoric acid for 30 seconds)
Number of subjects: 50
Study 27900987 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.3 mg/micronized progesterone (MP) 100 mg daily (Group A)
Number of subjects: 123
Study 27900987 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/MP 100 mg daily (Group B)
Number of subjects: 123
Study 27900987 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/dydrogesterone 10 mg daily (Group C)
Number of subjects: 123
Study 25248815 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels >3 mg/L
Number of subjects: 581
Study 25248815 — intervention group
Group type: COMPARATOR
Intervention: CRP levels <1 mg/L
Number of subjects: 581
Study 25248815 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels
Number of subjects: 581
Study 25248815 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 581
Study 25248815 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year MACE
Number of subjects: 581
Study 22763155 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of vitamin D2 (drops)
Number of subjects: 21
Study 22763155 — intervention group
Group type: COMPARATOR
Intervention: 800 IU of vitamin D3 (pills)
Number of subjects: 21
Study 20619140 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture applied to Zusanli and other acupoints, once a day.
Number of subjects: 63
Study 20619140 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide, 20 mg intramuscularly injected three times a day.
Number of subjects: 63
Study 17562523 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 81
Study 17562523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 81
Study 17562523 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 81
Study 17562523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 81
Study 16191351 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0% phenylephrine hydrochloride
Number of subjects: 19
Study 16191351 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide
Number of subjects: 19
Study 16191351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrin-P
Number of subjects: 19
Study 16191351 — intervention group
Group type: COMPARATOR
Intervention: 0.3% Tarivid
Number of subjects: 19
Study 11806983 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 delayed-intensification phases (DDI)
Number of subjects: 1204
Study 11806983 — intervention group
Group type: COMPARATOR
Intervention: Single delayed-intensification (DI)
Number of subjects: 1204
Study 11806983 — intervention group
Group type: COMPARATOR
Intervention: Single delayed-intensification with increased vincristine and prednisone pulses (DIVPI)
Number of subjects: 1204
Study 10063824 — intervention group
Group type: COMPARATOR
Intervention: 50% intensity group
Number of subjects: 27
Study 10063824 — intervention group
Group type: COMPARATOR
Intervention: 70% intensity group
Number of subjects: 27
Study 7577891 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase-treated maize-based weaning food
Number of subjects: 10
Study 7577891 — intervention group
Group type: COMPARATOR
Intervention: Maize-based weaning food (before amylase treatment)
Number of subjects: 10
Study 2202770 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (5KE X 1/W)
Number of subjects: 88
Study 2202770 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (5KE X 3/W)
Number of subjects: 88
Study 2202770 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (20KE X 3/W)
Number of subjects: 88
Study 2202770 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (all groups)
Number of subjects: 88
Study 6284566 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran diet
Number of subjects: 38
Study 6284566 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diet supplementation)
Number of subjects: 38
Study 30760125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 1315
Study 30760125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 1315
Study 30760125 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 1315
Study 30171280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 200 mg + Eltrombopag 50 mg
Number of subjects: 39
Study 30171280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 600 mg + Eltrombopag 50 mg
Number of subjects: 39
Study 30171280 — intervention group
Group type: COMPARATOR
Intervention: Eltrombopag 50 mg alone
Number of subjects: 39
Study 26988949 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus prasugrel
Number of subjects: 9294
Study 26988949 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 9294
Study 23777441 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2.5 mg/0.1 mL dose of subconjunctival bevacizumab immediately after surgery (group 1)
Number of subjects: 49
Study 23777441 — intervention group
Group type: EXPERIMENTAL
Intervention: Double 2.5 mg/0.1 mL injection of subconjunctival bevacizumab (one immediately after surgery and the second 15 days after surgery) (group 2)
Number of subjects: 49
Study 23777441 — intervention group
Group type: COMPARATOR
Intervention: No injection (group 3)
Number of subjects: 49
Study 22809589 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 138
Study 20823783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar support plus usual care
Number of subjects: 360
Study 17100978 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent hood
Number of subjects: 684
Study 17100978 — intervention group
Group type: COMPARATOR
Intervention: Short hood
Number of subjects: 684
Study 17100978 — intervention group
Group type: COMPARATOR
Intervention: No hood
Number of subjects: 684
Study 16376769 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index
Number of subjects: 0
Study 16376769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral E/e' ratio
Number of subjects: 0
Study 16376769 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise capacity (percentage of predicted peak VO2)
Number of subjects: 0
Study 12197843 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone (105 mg t.d.s.)
Number of subjects: 185
Study 12197843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg t.d.s.)
Number of subjects: 185
Study 12197843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.d.s.)
Number of subjects: 185
Study 9462386 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 20,000 units/day subcutaneously for at least 10 days
Number of subjects: 102
Study 9462386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 9462386 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 102
Study 8534649 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracapsular cataract extraction with IOL (343 patients)
Number of subjects: 662
Study 8534649 — intervention group
Group type: COMPARATOR
Intervention: Intracapsular cataract extraction without IOL (319 patients)
Number of subjects: 662
Study 8534649 — intervention group
Group type: EXPERIMENTAL
Intervention: Total study population (662 patients)
Number of subjects: 662
Study 2650602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat stitches
Number of subjects: 22
Study 2650602 — intervention group
Group type: COMPARATOR
Intervention: No fat stitches (implied control)
Number of subjects: 22
Study 648077 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 16
Study 648077 — intervention group
Group type: COMPARATOR
Intervention: Metaproterenol
Number of subjects: 16
Study 648077 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 16
Study 648077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31136474 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital image speckle correlation analysis
Number of subjects: 10
Study 31136474 — intervention group
Group type: COMPARATOR
Intervention: Physician assessment based on 2004 facial aesthetics consensus recommendations
Number of subjects: 10
Study 28455675 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger disc diameters (greater than 6 mm)
Number of subjects: 63
Study 28455675 — intervention group
Group type: COMPARATOR
Intervention: Disc diameter cutoffs (5, 6, 7, or 8 mm)
Number of subjects: 63
Study 28455675 — intervention group
Group type: COMPARATOR
Intervention: Disc volume removed
Number of subjects: 63
Study 26465985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU)
Number of subjects: 2259
Study 26465985 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1200 mg)
Number of subjects: 2259
Study 26465985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamin D3 (1000 IU) and calcium (1200 mg)
Number of subjects: 2259
Study 26465985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (neither agent)
Number of subjects: 2259
Study 23602247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bison (12 oz serving)
Number of subjects: 24
Study 23602247 — intervention group
Group type: COMPARATOR
Intervention: Beef (12 oz serving)
Number of subjects: 24
Study 23602247 — intervention group
Group type: COMPARATOR
Intervention: Beef (7 weeks chronic consumption)
Number of subjects: 24
Study 23602247 — intervention group
Group type: EXPERIMENTAL
Intervention: Bison (7 weeks chronic consumption)
Number of subjects: 24
Study 20689455 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit, berry, and vegetable concentrate (FVC), Juice Plus+® (NSA LLC, Collierville, TN), supplement
Number of subjects: 41
Study 20689455 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 41
Study 19626400 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times per day)
Number of subjects: 87
Study 16422738 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reminiscence group sessions held twice weekly for a six-week period
Number of subjects: 24
Study 16422738 — intervention group
Group type: COMPARATOR
Intervention: Activity (control) group
Number of subjects: 24
Study 15239968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation for 20 minutes
Number of subjects: 0
Study 15239968 — intervention group
Group type: COMPARATOR
Intervention: Chronic hypoxia in rats
Number of subjects: 0
Study 11700812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g
Number of subjects: 400
Study 11700812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 3 g
Number of subjects: 400
Study 11700812 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 3 g with additives ('Bio-C')
Number of subjects: 400
Study 11700812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.03 g vitamin C)
Number of subjects: 400
Study 9424970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (small doses)
Number of subjects: 34
Study 9424970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intraarticular morphine and bupivacaine
Number of subjects: 34
Study 9424970 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular drainage and patient-controlled analgesia
Number of subjects: 34
Study 9424970 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline addition, tourniquet use, time interval between injection and tourniquet release
Number of subjects: 34
Study 7962426 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with 200 x 10(6) purified paternal lymphocytes before pregnancy
Number of subjects: 44
Study 7962426 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 44
Study 7962426 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 44
Study 3239463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum with a self-help manual
Number of subjects: 197
Study 3239463 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help manual without gum
Number of subjects: 197
Study 3239463 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no further treatment)
Number of subjects: 197
Study 28743174 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention to facilitate posttraumatic growth (PTG)
Number of subjects: 205
Study 28743174 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=147)
Number of subjects: 205
Study 26777321 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (<2 h after randomization)
Number of subjects: 323
Study 26777321 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (2 to 72 h after randomization)
Number of subjects: 323
Study 26777321 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 323
Study 26777321 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 323
Study 25575728 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4mg daily for 5 days)
Number of subjects: 50
Study 25575728 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 50
Study 24085051 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical regimen (2% hydroquinone, 1% hydrocortisone and 0.05% tretinoin) with serial glycolic acid peeling
Number of subjects: 40
Study 24085051 — intervention group
Group type: COMPARATOR
Intervention: Topical regimen (2% hydroquinone, 1% hydrocortisone, 0.05% tretinoin)
Number of subjects: 40
Study 20945011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents
Number of subjects: 72
Study 20945011 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 72
Study 20945011 — intervention group
Group type: COMPARATOR
Intervention: Comparison between adolescents and adults
Number of subjects: 72
Study 18439174 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy plus additional tilt training sessions
Number of subjects: 82
Study 18439174 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 82
Study 16714461 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg 30 minutes before contrast medium administration)
Number of subjects: 91
Study 16714461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine (600 mg twice daily on the day of and the day before the examination)
Number of subjects: 91
Study 16714461 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents combined (theophylline and acetylcysteine)
Number of subjects: 91
Study 16714461 — intervention group
Group type: COMPARATOR
Intervention: Acetylcysteine
Number of subjects: 91
Study 16714461 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 91
Study 15534843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering drug
Number of subjects: 6595
Study 15534843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 11282901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose metoprolol CR/XL (25 mg once daily)
Number of subjects: 793
Study 11282901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg once daily)
Number of subjects: 793
Study 11282901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study 9001771 — intervention group
Group type: EXPERIMENTAL
Intervention: CSI soft toric contact lens
Number of subjects: 21
Study 9001771 — intervention group
Group type: COMPARATOR
Intervention: Optima soft toric contact lens
Number of subjects: 21
Study 7684157 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg once daily
Number of subjects: 100
Study 7684157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3324497 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nicergoline h.s.
Number of subjects: 24
Study 3324497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nicergoline b.i.d.
Number of subjects: 24
Study 3324497 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the 2-week placebo period)
Number of subjects: 24
Study 30958423 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group (n = 37)
Number of subjects: 74
Study 30958423 — intervention group
Group type: COMPARATOR
Intervention: Online group (n = 37)
Number of subjects: 74
Study 29467200 — intervention group
Group type: EXPERIMENTAL
Intervention: Salford Lung Study (SLS)
Number of subjects: 0
Study 26503414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 12 weeks
Number of subjects: 31
Study 26503414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 16 weeks
Number of subjects: 31
Study 26503414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1000-1200 mg divided twice daily for 24 weeks
Number of subjects: 31
Study 25237196 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 50 μg varicella-zoster virus glycoprotein E (gE) adjuvanted with AS01B
Number of subjects: 121
Study 25237196 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of gE adjuvanted with AS01E
Number of subjects: 121
Study 25237196 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of saline followed by 2 doses of gE/AS01B
Number of subjects: 121
Study 25237196 — intervention group
Group type: COMPARATOR
Intervention: 3 doses of saline
Number of subjects: 121
Study 22503429 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise regimen for 4 weeks
Number of subjects: 30
Study 20736679 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational intervention (CME activities)
Number of subjects: 133
Study 20736679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 133
Study 18809614 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel 200 mg/m² and carboplatin AUC 6 mg/mL/min every 3 weeks for four cycles
Number of subjects: 344
Study 18809614 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 344
Study 16278616 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17beta‐estradiol daily
Number of subjects: 222
Study 16278616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 11914254 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD) therapy
Number of subjects: 104
Study 11914254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104